Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data

Osteoporosis Clinical Trial

Official title:

Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04736693
• Other study ID #: 2018P002966-DUP-HORIZON-PFT
• Status: Completed
• Start date: September 22, 2020
• Est. completion date: February 18, 2021

Study information

• Verified date: July 2023
• Source: Brigham and Women's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Description:

This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to replicate, as closely as is possible in healthcare insurance claims data, the trial listed below/above. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates according to standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original RCT finding.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18028
• Est. completion date: February 18, 2021
• Est. primary completion date: February 18, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 65 Years and older

Eligibility

Criteria:

Please see https://drive.google.com/drive/folders/1WD618wrywYjEaXzfLTcuK-VCcnb6b-gV for full code and algorithm definitions.

Eligible cohort entry dates:

Zoledronic acid indication for treatment of postmenopausal women with osteoporosis was approved by FDA on Aug 20, 2007.

• For IBM MarketScan: Aug 21, 2007 - December 31, 2018 (end of available data)

• For Optum CDM: Aug 21, 2007 - Mar 31, 2020 (end of available data)

Inclusion Criteria:

• Postmenopausal women between the ages of 65 and 89 years

• Osteoporosis diagnosis

Exclusion Criteria:

• Bisphosphonate users

• Previous use of:

1. Any use of parathyroid hormone

2. Use of anabolic steroids or growth hormone within 6 months before cohort entry date OR

3. Use of oral or intravenous systemic corticosteroids within 12 months of cohort entry date

• Serious disease that may limit life expectancy to less than 6 months

• Malignant neoplasm diagnosis within 12 months prior to the cohort entry date

• Conditions that influence bone metabolism

• Treatment and Prevention of Glucocorticoid-Induced Osteoporosis

• Treatment of Paget's Disease of Bone

• Alcohol abuse/dependence OR Drug abuse/dependence OR Non-compliance

• Pregnancy

• Diagnosis and procedure for amputee of lower limb

• Use of Zoledronic acid within 450 days prior to the cohort entry date

• Use of Denosumab within 450 days prior to the cohort entry date

• Diagnosis of End-Stage Renal Disease OR Diagnosis and procedure for Kidney transplant

• Diagnosis of End-Stage Liver Disease: Cirrhosis, Hepatic decompensation

• Blindness or compromised vision

• Use of Abaloparatide within 450 days prior to the cohort entry date

• Use of Romosozumab within 450 days prior to the cohort entry date

Related Conditions & MeSH terms

• Osteoporosis

Intervention

Drug:
• Raloxifene
Raloxifene dispensing claim is used as the reference group.
• Zoledronic Acid
Zoledronic Acid dispensing claim is used as the exposure group.

Locations

Country	Name	City	State
United States	Brigham And Women's Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Brigham and Women's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with hip fracture	Please refer to attached protocol for full definition due to size limitations	Through study completion (earliest of 540 days or censoring)
Secondary	Number of patients with non-vertebral fracture	Please refer to attached protocol for full definition due to size limitations	Through study completion (earliest of 540 days or censoring)